LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.39 4.51

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.32

Максимум

1.4

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+87.97% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-21M 81M
Предишно отваряне	-3.12
Предишно затваряне	1.39

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.03.2026 г., 23:12 ч. UTC

Горещи акции

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12.03.2026 г., 22:15 ч. UTC

Печалби

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12.03.2026 г., 21:42 ч. UTC

Значими събития в новините

Stryker Says Cyberattack Disruption Is Continuing

12.03.2026 г., 21:29 ч. UTC

Значими събития в новините

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12.03.2026 г., 21:27 ч. UTC

Печалби

Adobe CEO to Depart as AI Boosts Sales -- Update

12.03.2026 г., 20:46 ч. UTC

Печалби

Adobe Posts Higher Sales With CEO Set to Depart

12.03.2026 г., 20:21 ч. UTC

Значими събития в новините

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12.03.2026 г., 23:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.03.2026 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12.03.2026 г., 22:13 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

12.03.2026 г., 22:13 ч. UTC

Пазарно говорене

Печалби

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12.03.2026 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12.03.2026 г., 21:04 ч. UTC

Печалби

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12.03.2026 г., 21:02 ч. UTC

Печалби

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12.03.2026 г., 21:02 ч. UTC

Печалби

Wheaton Precious Metals 4Q Sales $865M >WPM

12.03.2026 г., 21:02 ч. UTC

Печалби

Wheaton Precious Metals 4Q Net $558.3M >WPM

12.03.2026 г., 21:02 ч. UTC

Печалби

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12.03.2026 г., 20:57 ч. UTC

Пазарно говорене

Значими събития в новините

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

12.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12.03.2026 г., 20:10 ч. UTC

Печалби

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12.03.2026 г., 20:05 ч. UTC

Печалби

Adobe 1Q Rev $6.4B >ADBE

12.03.2026 г., 20:05 ч. UTC

Печалби

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

87.97% нагоре

12-месечна прогноза

Среден 2.5 USD 87.97%

Висок 3 USD

Нисък 2 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.